Opportunity Information: Apply for RFA HD 15 007
Apply for RFA HD 15 007
- The National Institutes of Health in the health income security and social services sector is offering a public funding opportunity titled "Isolation, Purification, and Synthesis of Human Milk Oligosaccharides with Antimicrobial Activity (R41)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on May 29, 2014 and posted on May 29, 2014.
- Applicants must submit their applications by Jul 31, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $750,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $150,000.00 in funding.
- Eligible applicants include: Small businesses.
- Other Eligible Applicants include the following Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This grant opportunity, titled "Isolation, Purification, and Synthesis of Human Milk Oligosaccharides with Antimicrobial Activity (R41)" (Funding Opportunity Number RFA-HD-15-007), is an NIH small business funding announcement aimed at pushing forward practical, scalable ways to discover and produce human milk oligosaccharides (HMOs) that can help fight microbes. HMOs are complex sugars naturally found in human milk, and the focus here is specifically on identifying which of these compounds have antimicrobial activity and then building the technical pathway to produce them at meaningful scale for downstream testing.
The announcement is structured around four main technical goals that applicants are expected to address through innovative research and development methods. First, it seeks new or improved approaches to identify HMOs with antimicrobial activity, meaning methods that can screen, prioritize, or otherwise pinpoint which HMOs have promising effects against relevant pathogens. Second, it calls for methods to isolate and purify the most promising HMOs, which implies an emphasis on producing sufficiently clean, well-defined materials suitable for rigorous testing and later development. Third, it requires detailed structural characterization of these HMOs, not just to confirm identity and purity, but to support the creation of a broader library of bioactive HMO structures. That library is intended to function as a set of templates or reference compounds that can guide future chemical synthesis or biological production (for example, enzymatic or microbial biosynthesis). Fourth, the FOA explicitly pushes applicants to think beyond discovery and into manufacturing readiness by ramping up synthetic procedures under Good Manufacturing Practice (GMP) conditions, with the goal of producing kilogram-scale batches that are appropriate for preclinical testing. In other words, the program is not only about finding interesting HMOs, but also about building a credible pipeline that can deliver enough material, made to appropriate quality standards, to support real preclinical development.
From an administrative and eligibility standpoint, this is a discretionary grant opportunity issued by the National Institutes of Health under the activity area of Child Health and Human Development research (CFDA 93.865, Eunice Kennedy Shriver National Institute of Child Health and Human Development). The funding instrument is a grant and the mechanism is R41, which corresponds to the Small Business Innovation Research (SBIR) Phase I pathway. Only small businesses are eligible to apply. Foreign (non-U.S.) entities and non-U.S. components of U.S. organizations are not eligible to apply, although foreign components, as defined in the NIH Grants Policy Statement, may be permitted in some circumstances. The FOA states there is no cost sharing or matching requirement.
In terms of funding levels and timing, the opportunity listed an estimated total funding amount of $750,000, with an award ceiling of $150,000. The opportunity was posted and created on May 29, 2014, with an original and current closing date of July 31, 2014, and an archive date of August 31, 2014, indicating it is no longer open. For those who need the original federal posting, an additional information link was provided through the NIH grants guide at http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-15-007.html. Contact information in the listing points applicants to the NIH Office of Extramural Research (OER) Webmaster emails for technical access or linking issues.
Overall, the practical intent of the announcement is to move antimicrobial HMOs closer to real-world use by funding small businesses that can combine discovery (finding and validating antimicrobial HMOs) with development (purification, structural definition, and creation of a reference library) and manufacturing scale-up (GMP-aligned production at kilogram quantities). The emphasis on preclinical testing readiness makes it clear NIH was looking for projects that could plausibly transition from early R&D into a translational pipeline, where consistent, well-characterized, scalable HMO production becomes the bridge between promising bioactivity and future therapeutic or preventive applications.
Frequently Asked Questions (FAQs)
What is the title of this grant opportunity?
The funding opportunity is titled "Isolation, Purification, and Synthesis of Human Milk Oligosaccharides with Antimicrobial Activity (R41)."
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is RFA-HD-15-007.
Which agency is offering this opportunity?
This is a discretionary grant opportunity issued by the National Institutes of Health (NIH).
Which NIH institute or program area is associated with the opportunity?
The opportunity is associated with Child Health and Human Development research and references the Eunice Kennedy Shriver National Institute of Child Health and Human Development (CFDA 93.865).
What is the funding mechanism?
The mechanism is R41, which corresponds to the Small Business Innovation Research (SBIR) Phase I pathway.
What type of funding instrument is this?
The funding instrument is a grant.
Who is eligible to apply?
Only small businesses are eligible to apply.
Are non-U.S. (foreign) organizations eligible to apply?
No. Foreign (non-U.S.) entities are not eligible to apply.
Are non-U.S. components of U.S. organizations eligible?
No. Non-U.S. components of U.S. organizations are not eligible to apply.
Are foreign components allowed in any form?
The opportunity indicates that foreign components, as defined in the NIH Grants Policy Statement, may be permitted in some circumstances.
Is cost sharing or matching required?
No. The FOA states there is no cost sharing or matching requirement.
What is the overall goal of the program?
The intent is to push forward practical, scalable ways to discover and produce human milk oligosaccharides (HMOs) that have antimicrobial activity, moving them closer to downstream testing and preclinical readiness.
What are HMOs in the context of this opportunity?
HMOs are complex sugars naturally found in human milk. This announcement focuses on identifying HMOs with antimicrobial activity and developing ways to produce them at meaningful scale.
What does the FOA mean by focusing on "antimicrobial activity"?
Within this opportunity, the focus is on identifying which HMOs have promising effects against relevant pathogens and building a pathway to produce those HMOs for further testing.
What kinds of projects is NIH trying to fund through this FOA?
Projects that combine discovery and development: identifying antimicrobial HMOs, isolating and purifying them, structurally characterizing them, building a library of defined structures, and ramping up production under GMP conditions toward kilogram-scale batches suitable for preclinical testing.
What are the main technical goals applicants are expected to address?
The announcement describes four main technical goals: (1) new or improved approaches to identify HMOs with antimicrobial activity, (2) methods to isolate and purify the most promising HMOs, (3) detailed structural characterization to confirm identity and support a broader library of bioactive HMO structures, and (4) ramping up synthetic procedures under GMP conditions to produce kilogram-scale batches appropriate for preclinical testing.
What does "identify HMOs with antimicrobial activity" mean in practice for this FOA?
It refers to developing methods that can screen, prioritize, or otherwise pinpoint which HMOs show promising antimicrobial effects against relevant pathogens.
Why does the FOA emphasize isolation and purification?
Because the goal is to produce sufficiently clean, well-defined HMO materials suitable for rigorous testing and later development.
What is meant by "structural characterization" in this announcement?
Structural characterization is described as more than confirming identity and purity; it is also intended to support the creation of a broader library of bioactive HMO structures.
What is the purpose of creating a library of bioactive HMO structures?
The library is intended to function as a set of templates or reference compounds that can guide future chemical synthesis or biological production approaches, such as enzymatic or microbial biosynthesis.
Does the FOA focus only on discovery, or also on manufacturing?
It explicitly pushes applicants beyond discovery and into manufacturing readiness by calling for scale-up of synthetic procedures under GMP conditions, with the goal of kilogram-scale batches for preclinical testing.
What does the FOA say about GMP and scale?
It emphasizes ramping up synthetic procedures under Good Manufacturing Practice (GMP) conditions and producing kilogram-scale batches that are appropriate for preclinical testing.
What is the estimated total funding amount for the opportunity?
The opportunity listed an estimated total funding amount of $750,000.
What is the award ceiling?
The award ceiling listed is $150,000.
When was the opportunity posted?
The opportunity was posted (and created) on May 29, 2014.
What was the closing date?
The original and current closing date listed was July 31, 2014.
Is this funding opportunity still open?
No. The listing includes an archive date of August 31, 2014, indicating the opportunity is no longer open.
Where can someone find the original NIH posting for this FOA?
An additional information link was provided through the NIH grants guide at http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-15-007.html.
Who is listed as the point of contact?
Contact information in the listing points to the NIH Office of Extramural Research (OER) Webmaster emails for technical access or linking issues.
What CFDA number is associated with this opportunity?
The opportunity references CFDA 93.865.
What is the practical intent of this FOA in translational terms?
The practical intent is to move antimicrobial HMOs closer to real-world use by funding small businesses that can create a credible pipeline from early R&D (discovery and validation) to development (purification, structural definition, reference library creation) and manufacturing scale-up (GMP-aligned production at kilogram quantities) to support preclinical testing readiness.
Browse more opportunities from the same category: Health Income Security and Social Services
Next opportunity: Survey Bat Community Composition at Hopewell Culture NHP Post White Nose Syndrome
Previous opportunity: Isolation, Purification, and Synthesis of Human Milk Oligosaccharides with Antimicrobial Activity (R43)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HD 15 007
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HD 15 007) also looked into and applied for these:
| Funding Opportunity |
|---|
| Male Contraceptive Development Program (U01) Apply for RFA HD 14 034 Funding Number: RFA HD 14 034 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Global Omics Approaches Targeting Adverse Pregnancy and Neonatal Outcomes Utilizing Existing Cohorts (R01) Apply for PAR 14 264 Funding Number: PAR 14 264 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Peripheral Blood Biomarkers of Chronic Traumatic Brain Injury in Human Subjects SBIR Direct Phase II (R44) Apply for RFA HD 15 012 Funding Number: RFA HD 15 012 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $750,000 |
| Innovative Therapies and Tools for Screenable Disorders in Newborns (R21) Apply for PAR 14 269 Funding Number: PAR 14 269 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Innovative Therapies and Tools for Screenable Disorders in Newborns (R03) Apply for PAR 14 271 Funding Number: PAR 14 271 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $50,000 |
| Pharmacogenetics, Pharmacoepigenetics and Personalized Medicine in Children (R01) Apply for PAR 14 274 Funding Number: PAR 14 274 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Medically Assisted Reproduction Investigation of Mechanisms Underlying the Adverse Outcomes and Development of New and Improved Methods to Overcome the Adverse Outcomes (R01) Apply for PAR 14 272 Funding Number: PAR 14 272 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Medically Assisted Reproduction Investigation of Mechanisms Underlying the Adverse Outcomes and Development of New and Improved Methods to Overcome the Adverse Outcomes (R21) Apply for PAR 14 273 Funding Number: PAR 14 273 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Pediatric Cardiac Genomics Consortium (UM1) Apply for RFA HL 15 012 Funding Number: RFA HL 15 012 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $269,000 |
| In vivo Methods for Assessing Placental Development and Function (SBIR) R43/R44 Apply for RFA HD 15 018 Funding Number: RFA HD 15 018 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| In vivo Methods for Assessing Placental Development and Function (STTR) R41/R42 Apply for RFA HD 15 019 Funding Number: RFA HD 15 019 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $2,000,000 |
| Obstetric Fetal Pharmacology Research Centers (OPRC) (U54) Apply for RFA HD 14 013 Funding Number: RFA HD 14 013 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $4,800,000 |
| Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care (R01) Apply for PA 14 312 Funding Number: PA 14 312 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care (R21) Apply for PA 14 311 Funding Number: PA 14 311 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care (R03) Apply for PA 14 313 Funding Number: PA 14 313 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $50,000 |
| NICHD Consortium for Research on Pediatric Trauma and Injury Prevention (R24) Apply for PAR 14 324 Funding Number: PAR 14 324 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $750,000 |
| Improving Health through Rehabilitation Robotic Technology (R43/R44) Apply for RFA HD 15 001 Funding Number: RFA HD 15 001 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Tools for Assessment and Improvement of Neurologic Outcomes in Perinatal Medicine (R41) Apply for RFA HD 15 005 Funding Number: RFA HD 15 005 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $150,000 |
| Tools for Assessment and Improvement of Neurologic Outcomes in Perinatal Medicine (R43) Apply for RFA HD 15 006 Funding Number: RFA HD 15 006 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $150,000 |
| Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers (U54) Apply for RFA AR 15 002 Funding Number: RFA AR 15 002 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $1,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HD 15 007", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.